Business
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
Ms. Tozier has held commercial leadership positions across the full product lifecycle and exceeded goals for 14 launches across 70-plus global markets, with
About this update from Outlook Therapeutics, Inc.
[{"type":"text","content":"Ms. Tozier has held commercial leadership positions across the full product lifecycle and exceeded goals for 14 launches across 70-plus global markets, with deep experience in ophthalmology and leadership for launching wet AMD/DME therapies. ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access. “We are pleased to strengthen our commercialization expertise with the addition of Alicia to our leadership team, bringing another seasoned ophthalmic marketer to guide and support our commercialization efforts. Of particular note, her successful track record with spearheading the introductions of two wet AMD therapies makes her an ideal addition to help us maximize the effectiveness of our potential ONS-5010 ophthalmic bevacizumab launch, if approved by the FDA for marketing,” said Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics. Ms. Tozier is a proven global commercialization leader with expertise across nine ophthalmology disease areas, and she has launched combination products spanning multiple modalities including medical devices, digital therapeutics and pharmaceuticals. Over the course of her career, she has led and scaled 60-plus person commercial launch teams and made significant contributions at leading companies such as Genentech, Astellas and Baxter. Most recently, she oversaw commercialization launch efforts for two wet AMD therapies. “Ms. Tozier’s background in combination products is not only mission-critical for our efforts with ONS-5010, but also for our anticipated development of a pre-filled syringe delivery system for ONS-5010, and for any future products we may consider,” added Mr. Evanson. “She will be responsible for leading the global commercial strategy, including marketing and market access, to ensure launch readiness across customers and channels.” In her role as SVP, Marketing and Market Access at Outlook Therapeutics, Ms. Tozier will report directly to Chief Commercial Officer Mr. Evanson and work cross-functionally with the leadership team. “I’m excited for the opportunity to leverage my extensive expe...